Can a treat-to-target strategy achieve better outcomes for patients with spondyloarthritis? Insights from the latest data.
Anti-Infliximab Antibodies Predict Response in Axial Spondyloarthritis
Pimentel et al. evaluated the influence of anti-infliximab antibodies on patients with axial spondyloarthritis. The researchers found that anti-infliximab antibodies were associated with decreased infliximab performance and difficulty tapering its dosage, as well as a good clinical response to a second, alternate tumor necrosis factor inhibitor.
Sacroiliitis on MRI: axSpA or Another Cause?
Magnetic resonance imaging (MRI) is the gold standard imaging modality for the detection of sacroiliitis, a hallmark of axial spondyloarthritis (axSpA). However, the specificity of MRI for axSpA has been questioned. Renson et al. found that structural MRI-detected SI joint lesions are frequently seen in healthy individuals.
Clinical Guidance & Recommendation Updates for Vasculitis, axSpA & More
In this EULAR 2022 session, new & revised treatment recommendations for ANCA-associated vasculitis, axial spondyloarthritis & rheumatoid arthritis were presented.
Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA
HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.
How Do Axial SpA & PsA with Axial Involvement Differ?
The differences between axial spondyloarthropathy (axSpA) and axial involvement in psoriatic arthritis (axPsA) have clinical and therapeutic implications. Three experts discussed the distinctions during ACR Convergence 2021.
Care of Patients with Spondyloarthritis
At the ACR Convergence session CARE: Spondyloarthritis, Alexis Ogdie, MD, presented key principles of diagnosis & management of patients with spondyloarthritis.
The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.
Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis
Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.
MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA
Three experts discuss the ins and outs of using magnetic resonance imaging to diagnose axial spondyloarthritis, particularly in individuals who lack clear clinical symptoms indicative of disease.
- 1
- 2
- 3
- 4
- Next Page »